Ziltivekimab ELISA Kit

Catalog No.

KDC15804

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human IL6 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Ziltivekimab in the sample competitively binds to the pre-coated protein with biotin-labeled Ziltivekimab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Ziltivekimab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Ziltivekimab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

62.5 - 2,000 ng/mL

Sensitivity

41.15 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	955.4	259.2	109.9	864.8	247.8	115.9
Standard deviation	117.7	23.1	20.1	96.5	20.0	20.7
CV (%)	12.3	8.9	18.3	11.2	8.1	17.9

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

COR-001, CAS: 2226654-05-1

Background

Ziltivekimab, a novel human IgG1, k antibody directed against IL-6 ligand, may improve inflammation and hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in patients receiving maintenance hemodialysis (HD), according to new study findings.

Seeking and treating inflammation in ischaemic heart disease: are we ready?, PMID:40248283

Inflammation in atherosclerotic cardiovascular disease: From diagnosis to treatment., PMID:40055964

"Anti-inflammatory Therapies in Atherosclerosis - Where are we going?"., PMID:39699771

Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?, PMID:39453604

Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial., PMID:39212045

Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review., PMID:39031302

Impacts of pro-inflammatory cytokines variant on cardiometabolic profile and premature coronary artery disease: A systematic review and meta-analysis., PMID:38634217

C-reactive protein, pharmacological treatments and diet: how to target your inflammatory burden., PMID:38277208

Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)., PMID:38088558

An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk., PMID:37716836

Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial., PMID:37211246

Innate Immunity System in Patients With Cardiovascular and Kidney Disease., PMID:37053283

Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial., PMID:36449307

Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis., PMID:35257900

Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine., PMID:34650351

The role and transformative potential of IL-19 in atherosclerosis., PMID:34600839

From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?, PMID:34352102

IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial., PMID:34015342

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease., PMID:33998272

Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial., PMID:33272965

A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD., PMID:35373026

Document Download

Ziltivekimab ELISA Kit.pdf